Anti Cd 20 Ocrevus denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Imposes Quantity Limits on Ocrelizumab

Blue Cross Blue Shield plans routinely apply quantity or frequency limits to ocrelizumab (Ocrevus) as a utilization-management measure. Because ocrelizumab is administered by infusion on a defined dosing schedule established in the FDA-approved prescribing label, a quantity-limit denial usually arises when the number of infusions or vials requested in a given period exceeds what the plan's system expects — sometimes because of a coding discrepancy, sometimes because the prescriber is managing a clinical situation that requires deviation from the standard schedule.

For the exact dosing schedule and infusion frequency that the FDA label authorizes, refer directly to the current prescribing information for ocrelizumab and your plan's coverage policy. Do not rely on any third-party summary.

## Why This Denial Is Appealable

Quantity-limit denials are adverse benefit determinations subject to your full appeal rights under ACA §2719 and ERISA §503. You have the right to a full-and-fair internal review and, if upheld, independent external review by a certified IRO. The external-review window is typically around four months from the adverse determination; confirm your plan's exact deadline. Expedited review is available when delay poses a serious health risk.

## Your Appeal Timeline

1. Request the denial letter and the plan's quantity-limit policy — understand the exact limit being applied and the policy rationale. 2. Confirm the quantity requested matches the FDA label schedule — if the request is within the labeled schedule, this may be a coding or authorization error correctable by resubmission. 3. If the prescriber is requesting a deviation from the standard schedule, file an internal appeal with clinical justification for the exception. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA prescribing label for ocrelizumab: document the approved dosing schedule. If the quantity requested is consistent with the label, note that explicitly in the appeal.
• Infusion administration records: dates, vial quantities administered, and the facility records for each prior infusion, showing compliance with the authorized schedule.
• Prescriber letter: if requesting a quantity that departs from the standard schedule, the neurologist must explain the specific clinical reason — for example, a re-initiation scenario — referencing chart evidence rather than population data.
• Diagnosis and disease-activity records: current neurology notes and MRI results that establish ongoing clinical need for the therapy.
• Prior authorization records: if a PA was previously granted for ocrelizumab, include that authorization to show a history of coverage at the established dose frequency.

## Criteria-Mapping Structure

Obtain the quantity-limit provision from BCBS's published policy and the FDA label schedule, then build a table:

| Plan Quantity Limit | Quantity Requested | FDA Label Alignment | Chart Justification | |---|---|---|---| | [From BCBS policy] | [From prescription/claim] | Consistent with label (attach label) | Neurology note, [Date] |

If the quantities are consistent with the FDA label, the appeal should lead with that fact prominently and attach the label as Exhibit A. If deviation is clinically necessary, the prescriber's letter is the cornerstone of the appeal.